A critical region in the mineralocorticoid receptor for aldosterone binding and activation by cortisol: Evidence for a common mechanism governing ligand binding specificity in steroid hormone receptors

Molecular Endocrinology

Volumn 21, Issue 4, 2007, Pages 817-828

  Rogerson, Fraser M ^a,c   Yao, Yi Zhou ^a   Elsass, Romi E ^a   Dimopoulos, Nektaria ^a   Smith, Brian J ^b   Fuller, Peter J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; STEROID HORMONE; HYBRID PROTEIN; LIGAND; STEROID RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING KINETICS; CHIMERA; HORMONE RECEPTOR INTERACTION; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; DRUG POTENTIATION; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN CONFORMATION;

ALDOSTERONE; AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; HYDROCORTISONE; LIGANDS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; RECEPTORS, MINERALOCORTICOID; RECEPTORS, STEROID; RECOMBINANT FUSION PROTEINS; TRANS-ACTIVATION (GENETICS);

EID: 34247897054     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2006-0246     Document Type: Article

References (36)

1. Fuller PJ, Young MJ 2005 Mechanisms of mineralocorticoid action. Hypertension 46:1227-1235
2. Gomez-Sanchez EP, Zhou M, Gomez-Sanchez CE 1996 Mineralocorticoids, salt and high blood pressure. Steroids 61:184-188
3. Young M, Funder JW 2000 Aldosterone and the heart. Trends Endocrinol Metab 11:224-226
4. Pitt B 2004 Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217:53-58
5. Lifton RP, Gharavi AG, Geller DS 2001 Molecular mechanisms of human hypertension. Cell 104:545-556
6. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FTF, Sigler PB, Lifton RP 2000 Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119-123
7. Gronemeyer H, Gustafsson JÅ, Laudet V 2004 Principles for modulation of the nuclear receptor superfamily. Nat Rev 3:950-964
8. Arriza JL, Weinberger C, Cerell, G, Glaser TM, Handelin BL, Housman DE, Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275
9. Pascual-Le Tallec L, Lombès M 2005 The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 19:2211-2221
10. Rogerson FM, Fuller PJ 2000 Mineralocorticoid action. Steroids 65:61-73
11. Pratt WB, Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360
12. Rupprecht R, Reul JMHM, van Steensel B, Spengler D, Söder M, Berning B, Holsboer F, Damm K 1993 Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol 247:145-154
13. Arriza JL 1991 Aldosterone action: perspectives from the cloning of the mineralocorticoid receptor. In: Bonvalet JP, Farman N, Lombès M, eds. Aldosterone: fundamental aspects. Paris: Colloque INSERM/John Libbey Eurotext; 13-21
14. Rogerson FM, Dimopoulos N, Sluka P, Chu S, Curtis AJ, Fuller PJ 1999 Structural determinants of aldosterone binding selectivity in the mineralocorticoid receptor. J Biol Chem 274:36305-36311
15. Fagart J, Huyet J, Pinon GM, Mayer C, Rafestin-Oblin M-E 2005 Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 12:554-555
16. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, Pearce KH, Stanley TB, Stewart EL, Trump RP, Willson TM, Williams SP 2005 A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem 280:31283-31293
17. Li Y, Suino K, Daugherty J, Xu HE 2005 Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol Cell 19:367-380
18. Vivat V, Gofflo D, Wurtz J-M, Bourguet W, Philibert D, Gronemeyer H 1997 Sequences in the ligand-binding domains of the human androgen and progesterone receptors which determine their distinct ligand identities. J Mol Endocrinol 18:147-160
19. Robin-Jagerschmidt C, Wurtz J-M, Guillot B, Gofflo D, Benhamou B, Vergezac A, Ossart C, Moras D, Philibert D 2000 Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and nodulate the receptor transactivation capacity. Mol Endocrinol 14:1028-1037
20. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H 1996 A canonical structure for the ligand-binding domain of nuclear receptors. Nature Struct Biol 3:206
21. Bruns CM, Hubatsch I, Ridderström M, Mannervik B, Tainer JA 1999 Human glutathione transferase A4-4 crystal structures and mutagenesis reveal the basis of high catalytic efficiency with toxic lipid peroxidation products. J Mol Biol 288:427-439
22. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105
23. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, Calles K, Engstrom O, Harlan J, Muchmore S, Ramqvist AK, Thorell S, Ohman L, Greer J, Gustafsson JA, Carlstedt-Duke J, Carlquist M 2003 The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 278:22748-22754
24. White PC, Mune T, Agarwal AK 1997 11β-Hhydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18:135-156
25. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M 1998 Brain corticosteroid receptor balance in health and disease. Endocr Rev 19:269-301
26. Baker ME 1997 Steroid receptor phylogeny and vertebrate origins. Mol Cell Endocrinol 135:101-107
27. Sloman KA, Desforges PR, Gilmour KM 2001 Evidence for a mineralocorticoid-like receptor linked to branchial chloride cell proliferation in freshwater rainbow trout. J Exp Biol 204:3953-3961
28. Rogerson FM, Yao Y-Z, Smith BJ, Dimopoulos N, Fuller PJ 2003 Determinants of spironolactone binding specificity in the mineralocorticoid receptor. J Mol Endocrinol 31:573-582
29. Rogerson FM, Yao Y, Smith BJ, Fuller PJ 2004 Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clin Exp Pharmacol Physiol 31:704-709
30. Martinez ED, Pattabiraman N, Danielsen M 2005 Analysis of the hormone-binding domain of steroid receptors using chimeras generated by homologous recombination. Exp Cell Res 308:320-333
31. Lind U, Greenidge P, Gustafsson J-Å, Wright APH, Carlstedt-Duke J 1999 Valine 571 functions as a regional organizer in programming the glucocorticoid receptor for differential binding of glucocorticoids and mineralocorticoids. J Biol Chem 274:18515-18523
32. Carlsson P, Koehler KF, Nilsson L 2005 Glucocorticoid receptor point mutation V571M facilitates coactivator and ligand binding by structural rearrangement and stabilization. Mol Endocrinol 19:1960-1977
33. Rogerson FM, Brennan FE, Fuller PJ 2003 Dissecting mineralocorticoid receptor structure and function. J Steroid Biochem Mol Biol 85:389-396
34. Fuller PJ, Smith BJ, Rogerson FM 2004 Cortisol resistance in the New World revisited. Trends Endocrinol Metab 15:296-299
35. Nettles KW, Sun J, Radek JT, Sheng S, Rodriguez AL, Katzenellenbogen JA, Katzenellenbogen BS, Greene GL 2004 Allosteric control of ligand selectivity between estrogen receptors α and β: implications for other nuclear receptors. Mol Cell 13:317-327
36. McPherson GA, Molenaar P, Raper C, Malta E 1983 Analysis of dose-response curves and calculation of agonist dissociation constants using a weighted nonlinear curve fitting program. J Pharmacol Methods 10:231-241